Hanmi Pharm. Co., Ltd.
Financials
Valuation Metrics
Hanmi Pharm. Co., Ltd.'s Market Cap is ₩4.8T. At end of 2025 it was ₩5.8T. Ranked #101 of 2,436 in KR market (top 4%), #95 of 787 on KOSPI (top 12%), #7 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.84T KRW | KR#101/2,436 Sec#7/234 |
| Revenue | 1.55T KRW | KR#301/2,436 Sec#10/234 |
| Net Income | 193.56B KRW | KR#137/2,436 Sec#7/234 |
| Total Assets | 2.23T KRW | KR#280/2,436 Sec#10/234 |
| Net Assets | 1.48T KRW | KR#216/2,436 Sec#9/234 |
| Employees | 2,388 | KR#122/2,436 Sec#3/234 |
| Value | ||
| P/E | 25.02x | KR#1,188/2,436 Sec#70/234 |
| P/B | 3.27x | KR#2,141/2,436 Sec#170/234 |
| PEG | 1.74x | KR#790/2,436 Sec#51/234 |
| P/S | 3.13x | KR#2,021/2,436 Sec#128/234 |
| EV/EBITDA | 20.25x | KR#1,021/2,436 Sec#59/234 |
| FCF Yield | 2.69% | KR#1,020/2,436 Sec#68/234 |
| Profitability | ||
| ROE | 13.09% | KR#328/2,436 Sec#20/234 |
| ROA | 8.69% | KR#279/2,436 Sec#21/234 |
| Op. Margin | 16.29% | KR#238/2,436 Sec#21/234 |
| Revenue Growth | 0.51% | KR#1,412/2,436 Sec#134/234 |
| Earnings Growth | 14.40% | KR#798/2,436 Sec#51/234 |
| Financial Health | ||
| Debt Ratio | 50.54% | KR#179/2,436 Sec#22/234 |
| Total Debt | 408.98B KRW | KR#338/2,436 Sec#12/234 |
| FCF | 130.05B KRW | KR#150/2,436 Sec#8/234 |
| Cash | 140.40B KRW | KR#363/2,436 Sec#15/234 |
| Current Ratio | 1.54x | KR#1,273/2,436 Sec#138/234 |
| Net Debt/EBITDA | 1.06x | KR#804/2,436 Sec#54/234 |
| Dividend | ||
| Div. Yield | 0.58% | KR#1,263/2,436 Sec#80/234 |
| Div. Growth | 60.00% | KR#194/2,436 Sec#6/234 |
| Performance | ||
| 1Y Return | 36.71% | KR#308/2,436 Sec#26/234 |
| 1M Return | -18.09% | KR#2,127/2,436 Sec#213/234 |
| From 52W High | -41.58% | KR#832/2,436 Sec#59/234 |
| 1Y MDD | -50.24% | KR#946/2,436 Sec#79/234 |
| Trading | ||
| Volume | 93,357 shares | KR#978/2,436 Sec#97/234 |
| Foreign Own. | 15.21% | KR#314/2,436 Sec#19/234 |
| Per Share | ||
| EPS | 13,460 KRW | KR#58/2,436 Sec#6/234 |
| BPS | 102,445 KRW | KR#125/2,436 Sec#6/234 |
Company Info
Hanmi Pharmaceutical was established in 2010 through a spin-off of its pharmaceutical manufacturing and sales division, comprising three domestic and international subsidiaries. It produces Rosuzet, Amozaltan, and Esomezol, while Hanmi Fine Chemical exports cephalosporin-based antibiotics globally, and Beijing Hanmi Pharmaceutical Co., Ltd. sells various products. The company focuses on innovative new drug development, having acquired numerous patents by 2025, and is optimizing manufacturing processes and saving energy to reduce greenhouse gas emissions by 30% by 2030. Hanmi Pharmaceutical is headquartered in Hwaseong-si, Gyeonggi-do.